磺脲类药物对心脏线粒体KATP通道亲和力与2型糖尿病主要不良心血管事件风险的关系
基于台湾全民健康保险数据库的队列研究,纳入2007至2016年间起始磺脲类单药治疗的2型糖尿病患者,经1:1倾向评分匹配后比较心脏线粒体KATP通道高亲和力(格列本脲、格列吡嗪)与低亲和力(格列齐特、格列美脲)磺脲类各33,727例。高亲和力组三点主要不良心血管事件(MACE)风险显著升高(aHR 1.21,95%CI 1.03-1.44),缺血性卒中(aHR 1.23,95%CI 1.02-1.50)和心血管死亡(aHR 2.61,95%CI 1.31-5.20)风险亦升高,心肌梗死无显著差异(aHR 1.04,95%CI 0.75-1.46)。
要点
- 心脏mitoKATP通道高亲和力磺脲类与三点MACE风险升高相关(aHR 1.21,95%CI 1.03-1.44)。
- 高亲和力磺脲类与缺血性卒中(aHR 1.23,95%CI 1.02-1.50)和心血管死亡(aHR 2.61,95%CI 1.31-5.20)风险升高相关。
- 高亲和力磺脲类与心肌梗死风险无显著相关(aHR 1.04,95%CI 0.75-1.46)。
核心结论
- 在全国性糖尿病人群中,心脏mitoKATP通道高亲和力磺脲类相比低亲和力磺脲类与MACE风险升高相关。
研究设计与样本
- 使用台湾全民健康保险数据库的队列研究,纳入2007至2016年间起始磺脲类单药治疗的2型糖尿病患者。
- 经1:1倾向评分匹配后,心脏mitoKATP通道高亲和力(格列本脲和格列吡嗪)与低亲和力(格列齐特和格列美脲)磺脲类新用户各33,727例。
- 采用Cox比例风险模型估计调整风险比(aHR)和95%CI。
主要发现
- 高亲和力磺脲类与三点MACE风险显著升高相关(aHR 1.21,95%CI 1.03-1.44)。
- 高亲和力磺脲类与缺血性卒中风险显著升高相关(aHR 1.23,95%CI 1.02-1.50)。
- 高亲和力磺脲类与心血管死亡风险显著升高相关(aHR 2.61,95%CI 1.31-5.20)。
- 高亲和力磺脲类与心肌梗死风险无显著相关(aHR 1.04,95%CI 0.75-1.46)。
- 疗程-反应分析显示MACE风险在治疗90天内最高(aHR 4.67,95%CI 3.61-6.06)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Previous studies have revealed an intraclass difference in major adverse cardiovascular events (MACE) among sulfonylureas. In vitro and ex vivo studies reported several sulfonylureas to exhibit high-affinity blockage of cardiac mitochondrial ATP-sensitive potassium (mitoKATP) channels and could interfere with ischemic preconditioning, the most important mechanism of self-cardiac protection. However, no studies have examined whether these varying binding affinities of sulfonylureas could account for their intraclass difference in MACE. We compared mitoKATP channel high-affinity versus low-affinity sulfonylureas regarding the MACE risk in real-world settings. RESEARCH DESIGN AND METHODS: Using the Taiwan nationwide health care claims database, patients with type 2 diabetes initiating sulfonylurea monotherapy between 2007 and 2016 were included in the cohort study. A total of 33,727 new mitoKATP channel high-affinity (glyburide and glipizide) and low-affinity (gliclazide and glimepiride) sulfonylurea users, respectively, were identified after 1:1 propensity score matching. Cox proportional hazard models were used to estimate adjusted hazard ratios (aHRs) and 95% CI. RESULTS: MitoKATP channel high-affinity sulfonylureas were associated with a significantly increased risk of three-point MACE (aHR 1.21 [95% CI 1.03-1.44]), ischemic stroke (aHR 1.23 [95% CI 1.02-1.50]), and cardiovascular death (aHR 2.61 [95% CI 1.31-5.20]), but not with that of myocardial infarction (aHR 1.04 [95% CI 0.75-1.46]). The duration-response analyses revealed the highest MACE risk to be within 90 days of therapy (aHR 4.67 [95% CI 3.61-6.06]). CONCLUSIONS: Cardiac mitoKATP channel high-affinity sulfonylureas were associated with an increased MACE risk compared with low-affinity sulfonylureas in a nationwide population with diabetes.
引用
- Wang MT, Huang YL, Lai JH, et al. Association Between Specificity of Sulfonylureas to Cardiac Mitochondrial KATP Channels and the Risk of Major Adverse Cardiovascular Events in Type 2 Diabetes. Diabetes Care. 2022. PMID: 35294529. doi:10.2337/dc21-1779
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。